Abbott Laboratories stock in focus after Oncodetect launch

Published on 10/31/2026 at 10:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Abbott Laboratories stock is in focus after the company launched its next-generation Oncodetect cancer test in the United States. Quarterly growth also accelerated.

Abbott combines diagnostics and growth updates

Abbott launched the next-generation Oncodetect cancer test in the United States on October 26.
Third-quarter comparable sales rose 7.0 percent, while adjusted diluted earnings per share reached 1.42 US dollars.
The diagnostics expansion adds a new commercial angle as Abbott builds on its Exact Sciences acquisition.

Abbott Laboratories, US0028241000, Illustration mit AI erstellt.

Abbott Laboratories launched its next-generation Oncodetect molecular residual disease test in the United States on October 26, adding a new diagnostics product to its portfolio. The company also reported stronger third-quarter growth on October 21, giving investors two business developments to weigh as the week ended.

Cancer testing expands Abbott's reach

According to Abbott's announcement, the test uses personalized, tumor-informed whole-genome sequencing to track cancer signals during and after treatment. It can follow up to 5,000 patient-specific variants and is designed to detect circulating tumor DNA at levels below one part per million.

The product is available for patients with solid tumors and requires a health-care provider's order. Abbott said the test has not been cleared or approved by the U.S. Food and Drug Administration and is performed at Genomic Health's laboratory, which is certified under CLIA regulations.

Third-quarter growth sharpens outlook

Abbott's third-quarter sales rose 14.5 percent on a reported basis and 7.0 percent on a comparable basis, according to the company's results release. Adjusted diluted earnings per share reached 1.42 US dollars, while reported diluted earnings per share were 0.53 US dollars.

The company reaffirmed its full-year adjusted earnings outlook. For investors, the combination of broad quarterly growth and a new cancer-diagnostics product keeps execution across Abbott's operating businesses at the center of the investment case.

Abbott Laboratories stock traded at 95.13 euros on Lang & Schwarz at 10:30 Berlin time on Saturday, October 31, 2026.